Latest Breaking News On - Novel emerging molecular - Page 1 : comparemela.com

Johnson & Johnson s Investigational TAR-200 Granted U S FDA Breakthrough Therapy Designation for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer

/PRNewswire/ Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted TAR-200 Breakthrough Therapy Designation (BTD).

United statesUnited kingdomObrian kenneyClin urolKiran patelIndianj urolPrnewswire johnsonExchange commissionJanssen biotech incDrug administrationJanssen research developmentEuropean society for medical oncology annual congressAmerican urological association annual meeting abstractNone of janssen research developmentClinical developmentBreakthrough therapy designation

Johnson & Johnson : Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor -October 23, 2023 at 07:22 am EDT

News Release Media Contacts: Suzanne Frost +1 416-317-0304 Brian Kenney +1 215-620-0111 .

United kingdomJames wf cattoIndianj urolClin urolObrian kenneyKiran patelJnjinnovmedand janssenExchange commissionDrug administrationClinical developmentCompanies of johnsonEuropean society for medical oncologyDepartment of oncologyEuropean society for medical oncology congressNone of janssen research developmentJanssen research development

First Results with Erdafitinib-Releasing Intravesical Delivery System (TAR-210) Show Early Evidence of Positive Clinical Activity in Patients with Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations

Investigational TAR-210 first-in-human results highlight the potential for local sustained release of erdafitinib with a novel intravesical delivery system Phase 1 results show a manageable safety profile with limited systemic toxicity, and early complete responses in patients with high-risk and intermediate-risk NMIBC MADRID, Oct. 22, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & […]

Comunidad autonoma de catalunaObrian kenneyJeffrey infanteEuropean society for medical oncologyCompanies of johnsonJanssen biotech incJanssen pharmaceutical companies of johnsonTranslational researchExchange commissionOncology early clinical developmentNone of janssen research developmentJanssen research developmentJanssen pharmaceutical companiesLate breaking mini oral presentation sessionEuropean societyMedical oncology

TAR-200 Intravesical Delivery System Results Show 77 Percent Complete Response Rate in Patients with Bacillus-Calmette-Guérin Unresponsive, High-Risk Non-Muscle-Invasive Bladder Cancer

Phase 2b SunRISe-1 study results showed sustained, durable complete responses beyond one year with intravesical gemcitabine delivery system MADRID, Oct. 22, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that data from the Phase 2b SunRISe-1 study evaluating the efficacy and safety of TAR-200 monotherapy in patients with Bacillus Calmette-Guérin (BCG)-unresponsive, […]

United kingdomUnited statesObrian kenneyClin urolAndrea necchiScientific instituteNone of janssen research developmentJanssen research developmentExchange commissionSalute san raffaele universityEuropean society for medical oncologyJanssen pharmaceutical companies of johnsonAmerican urological association annual meetingJanssen biotech incCompanies of johnsonJanssen pharmaceutical companies

First Results with Erdafitinib-Releasing Intravesical Delivery System (TAR-210) Show Early Evidence of Positive Clinical Activity in Patients with Non-Muscle-Invasive Bladder Cancer with Select Fibrob

First Results with Erdafitinib-Releasing Intravesical Delivery System (TAR-210) Show Early Evidence of Positive Clinical Activity in Patients with Non-Muscle-Invasive Bladder Cancer with Select Fibrob
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Comunidad autonoma de catalunaJeffrey infanteObrian kenneyNone of janssen research developmentTranslational researchOncology early clinical developmentJanssen research developmentEuropean society for medical oncologyJanssen biotech incCompanies of johnsonJanssen pharmaceutical companies of johnsonExchange commissionJanssen pharmaceutical companiesLate breaking mini oral presentation sessionEuropean societyMedical oncology